Pakistan’s Ambassador to China, Khalil Hashmi, has announced the successful conclusion of the 6th Pakistan-China B2B Investment Conference on Pharmaceuticals, Biotechnology and Healthcare, revealing that enterprises from both countries signed more than 120 Memorandums of Understanding (MoUs), joint ventures, and commercial agreements valued at over US$1.7 billion.
Pakistan-China Pharma B2B Conference secures over $1.7 billion in investment commitments
BEIJING, July 20 (APP):Pakistan’s Ambassador to China, Khalil Hashmi, has announced the successful conclusion of the 6th Pakistan-China B2B Investment Conference on Pharmaceuticals, Biotechnology and Healthcare, revealing that enterprises from both countries signed more than 120 Memorandums of Understanding (MoUs), joint ventures, and commercial agreements valued at over US$1.7 billion.
Sharing the update on the social media platform X, Ambassador Hashmi said the agreements span a wide range of sectors, including biotechnology, vaccines, biologics, active pharmaceutical ingredients (APIs), medical devices, pharmaceuticals, Traditional Chinese Medicine (TCM), clinical research, and other allied healthcare industries.
He described the conference as a landmark collaborative initiative conceived by the Pakistan Embassy in China and its four Consulates.
The event was made possible through the continued support of Prime Minister Shehbaz Sharif, Deputy Prime Minister and Foreign Minister Ishaq Dar, the Minister for National Health, and the Adviser to the Prime Minister on Industries.
Ambassador Hashmi also acknowledged the contributions of the Ministry of National Health Services, Regulations and Coordination (MNHSR&C), the Drug Regulatory Authority of Pakistan (DRAP), the Trade Development Authority of Pakistan (TDAP), the Board of Investment (BOI), the Special Investment Facilitation Council (SIFC), and industry representatives from the health sectors of both Pakistan and China.
He said the conference has provided fresh momentum to Pakistan–China business collaboration by promoting investment, technology transfer, industrial partnerships, and deeper economic integration between the pharmaceutical industries of the two countries.
Looking ahead, Ambassador Hashmi said follow-up efforts will begin shortly to facilitate the conversion of signed MoUs into binding contracts and commercial agreements, with the ultimate goal of translating these commitments into operational factories, manufacturing plants, and long-term investment projects.
